NEW YORK (GenomeWeb) - Accelerate Diagnostics today said that revenues for its second quarter rose 46 percent.

According to a document filed with the US Securities and Exchange Commission, for the three months ended June 30, the Tucson, Arizona-based molecular diagnostics company said that revenues increased to $19,000 from $13,000 a year ago, composed entirely of revenues associated with licensing agreements.

The firm's net loss in the quarter was $12.3 million, or $.27 per share, compared to a net loss of $8.2 million, or $.19 per share, in the prior-year period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.